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D Abstract - We have tested the etTect of donor bone mar-
row cell (DBMC) infusion on the survival of pancreatic islet 
allografts in the rat, without the use of cytoablative recipi-
ent conditioning. Lewis and diabetic Brown Norway rats 
were used as donors and recipients, respectively. Donor 
islets were placed beneath the left renal capsule. Infusion of 
DBMC and temporary immunosuppression followed by de-
layed islet transplantation resulted in indefinite survival of 
all islet grafts (MST >180 days). Control animals demon-
strated recurrent hyperglycemia (islet allografts rejection). 
Donor bone marrow derived cells were detected in the 
spleen and cervical lymph nodes of BN recipients of LEW 
bone marrow but not in the recipients of islet transplants 
alone. Second set full thickness skin grafts were performed 
in normal BN and in recipients of a previously successful 
ITX. Donor specific skin grafts were accepted in the ani-
mals that had received DBMC 40 days before the islet al-
lograft, while animals receiving DBMC at the time of the 
islet allograft rejected the donor specific skin graft similarly 
to the controls. However, these animals did not reject a 
second set donor-specific islet transplant. The results indi-
cate that radiation conditioning of the recipients was not 
necessary to induce microchimerism and graft acceptance 
in this rodent model of islet allotransplantation. 
D Keywords - Tolerance; Islet; Allograft; Bone marrow. 
Indefinite survival of pancreatic islet grafts was recently 
reported in rodents following radiation conditioning of 
the recipients and hematopoietic reconstitution with bone 
marrow cells of donor origin (3,6,8), These models of 
bone marrow conditioning successfully induced drug-
free acceptance of donor specific pancreatic islet allo-
grafts, However, the use of lethal or sublethal radiation 
treatment severely limits the applicability of this ap-
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proach in humans, Recent experimental evidence indi-
cates that radiation conditioning of the recipient may not 
be necessary for stem cell engraftment (1,2,7), We have 
therefore tested the effect of donor bone marrow infusion 
on the survival of pancreatic islet allografts in the rat, 
without the use of cytoablative recipient conditioning, 
Adult male Lewis (LEW, RTll) and Brown Norway 
(BN, RTln) rats were used as donors and recipients, 
respectively. The recipients were made diabetic by one 
injection of streptozotocine (65 mg/kg, IV) and only ani-
mals with plasma blood glucose levels greater than 350 
mg/dL for 2 consecutive days were used as recipients of 
islet grafts. The islets were obtained by an automated 
method (4) as previously described (6). Fourteen hun-
dred (1400) highly purified islets of an average diameter 
of 150 f.L were placed beneath the left renal capsule. 
Donor bone marrow cell (DBMC) infusion consisted of 
the IV injection of 2.5 x 108 cells either 40 days before 
or at the time of islet transplantation (ITX), The recipient 
rats were divided into the following groups. The animals 
in Group 1 received only the renal subcapsular islet graft 
without any immunosuppression (n = 5), In Group 2, 
temporary immunosuppression with FK506 (I mg/kg, 
1M) on Days -39 to -26, -19, and -12 (Treatment A) 
was followed by ITX on Day 0 (12 days after discon-
tinuation of immunosuppression) (n = 4), In Group 3, 
temporary immunosuppression with FK506, was admin-
istered on days 0 to 13, 21 and 28 days after ITX (Treat-
ment B; n = 5). In Group 4, DBMC infusion and ITX 
were performed simultaneously, in association with the 
temporary immunosuppression regimen of Treatment B 
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(n = 4). In Group 5, DBMC infusion was followed by 
the temporary immunosuppression regimen (Treatment 
A). The ITX occurred 12 days after the last FK-506 
injection and 40 days following DBMC infusion (n = 5). 
In Groups I and 2 all animals demonstrated recurrent 
hyperglycemia (islet allografts rejection) within 2 wk 
after ITX. There was no significant difference between 
these two groups. In Group 3, as was predictable, the 
addition of temporary immunosuppression significantly 
prolonged the survival of the islet allografts with a mean 
survival time (MST ± SD) of 76.6 ± 15.0 days. The ITX 
survival in this group was significantly prolonged com-
pared to Groups 1 and 2 (p < 0.0 I; ANOV A). Neverthe-
less, all animals eventually demonstrated recurrent hy-
perglycemia, indicating delayed islet rejection. In Group 
4, there was marked prolongation of islet allograft sur-
vival to 145.8 ± 8.5 days. ITX survival was significantly 
prolonged compared to both Groups I and 2 (p < 0.01) 
and to Group 3 (p < 0.05). Nephrectomy of all kidneys 
bearing the islet grafts produced a rapid return to the 
diabetic state, indicating that the transplanted islets were 
responsible for maintaining normoglycemia. Two ani-
mals of this group received a second ITX from the same 
donor strain in the contralateral kidney (right), These 
second set grafts were also accepted and normalized 
plasma glucose levels without evidence of rejection 
(MST >90 days). In Group 5, infusion of DBMC and 
temporary immunosuppression (Treatment A) followed 
by delayed islet transplantation resulted in indefinite sur-
vival of all islet grafts (MST >180 days). Histology of 
the renal subcapsular grafts revealed well-preserved in-
sulin-producing tissue (Fig. I). Donor bone marrow de-
rived cells were detected in the spleen and cervical 
lymph nodes of BN recipients of LEW bone marrow 
using a monoclonal antibody (L-21-6) that reacts with 
the invariant chain of Class JI MHC molecules of LEW 
and m0st other rat strains, but not BN (l,5). Donor bone 
marrow derived cells were identified in the recipients of 
DBMC, but not in the recipients of islet transplants 
alone. Nevertheless, donor-deri ved cells were not detect-
able by flow cytometric analysis of peripheral blood leu-
kocytes in recipients of DBMC, indicating that micro-
chimerism was present at a level less than 1%. 
Second set fu 11 thickness skin grafts were performed in 
normal BN and in recipients of a previously successful 
ITX. In the latter cases, the skin grafts were performed 4 
wk following nephrectomy of the kidneys bearing the 
functioning islet allografts. The results are summarized 
in Table 1 and indicate that, as expected, control animals 
rejected both donor and third party skin grafts. To our 
surprise, donor-specific skin grafts were accepted only in 
the animals of Group 5, that had received DBMC 40 days 
before the islet allograft. The animals in Group 4 rejected 
the donor-specific skin graft similarly to the controls. 
However, as indicated earlier, these animals did not re-
ject a second set donor-specific islet transplant. Although 
it is not possible to draw a firm conclusion from the small 
number of animals we studied, the results raise the ques-
tion that donor specific and/or organ specific tolerance 
can be dependent upon the timing of DBMC infusion. 
In summary, the results indicate that radiation condi-
tioning of the recipients was not necessary to induce 
prolonged microchimerism and graft acceptance in this 
rodent model of islet allotransplantation, and confirms 
the results recently reported by Demetris et al. on bone 
marrow and whole organ allotransplantation (1). 
Fig. 1. Renal subcapsular islet allograft (dmk) stained for insulin (immunoperoxidase) 220 days following transplantalion. Original 
magnification x200. 
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Table J. Skin graft survival 
Skin Graft Survival (Days) 
ACI LEW BN 
Recipients skin skin skin 
Normal BN 10, 1O 10,11 >70,>70 
(Controls) 
Group 4 10, 12 II, 12 >70,>70 
(lTX + DBMC + Treatment A) 
Group 5 12, 12 >70.>70 >70.>70 
(DBMC + Treatment B ---> rTX) 
The paradigm of "making space" by cytoablative 
conditioning has been recently challenged, indicating 
that it is possible to infuse a high dose of donor marrow 
to successfully and permanently repopulate a recipient 
without radiation treatment (2,7). These results may be 
even more relevant when the target of DBMC treatment 
is the generation of a microchimeric state. Our results 
may be of assistance in defining new strategies for trans-
plantation of donor hematopoietic cells to enhance allo-
graft survival. 
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